Table 1.

Summary characteristics of included trials

	Crohn’s disease	Ulcerative colitis
	[n = 124]	[n = 71]
Trial design, n [%]
Induction	70 [56.5]	50 [70.4]
Maintenance	22 [17.7]	4 [5.6]
Integrated induction/maintenance	32 [25.8]	17 [23.9]
Trial phase, n [%]
Phase I	5 [4.0]	5 [7.0]
Phase II	57 [46.0]	32 [45.1]
Phase III	62 [50.0]	34 [47.9]
Trial setting, n [%]
Single centre	9 [7.3]	5 [7.0]
Multicentre, single nation	29 [23.4]	16 [22.5]
Multicentre, multinational	86 [69.4]	50 [70.4]
Active comparator, n [%]
Aminosalicylate	10 [8.1]	15 [21.1]
Corticosteroid	8 [6.5]	6 [8.5]
Immunosuppressant	11 [8.9]	2 [2.8]
Biologic	57 [46.0]	28 [39.4]
Oral small molecule	13 [10.5]	7 [9.9]
Other	25 [20.2]	13 [18.3]
Total patients, n
Total patients randomized	26 042	16 798
Patients randomized to active treatment	15 680	10 934
Patients randomized to placebo	8987	5563
Median follow-up duration [wk, range]	17 [2–112]	10 [4–96]

SD standard deviation